Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ex Vivo Expansion of CD8+CD56+ and CD8+CD56- Natural Killer T Cells Specific for MUC1 Mucin

Ex Vivo Expansion of CD8+CD56+ and CD8+CD56- Natural Killer T Cells Specific for MUC1 Mucin Prostate cancers express MUC1, but nearly all metastatic cells lack HLA class I molecules. Thus, a lymphocyte population that can sense its antigenic environment, while also able to react to stimuli of natural killer (NK) cells, may be a more versatile effector cell population for antitumor immune responses. Herein, we report that tumor-specific MUC1 peptide, interleukin 2, and interleukin 12 act synergistically to stimulate the ex vivo expansion of CD8 + CD56 - T cells and CD8 + CD56 + natural killer T (NKT) cells from the peripheral blood mononuclear cells of prostate cancer patients, as well as healthy male and female donors. Both the CD56 + NKT cells and CD56 - T cells lysed allogeneic mucin-bearing target cells, as well as NK target cells, but not lymphokine-activated killer target cells. However, the CD56 + NKT cells displayed a 2-fold greater cytolytic activity than the CD56 - T cells. The mucin-specific cytolytic activity and NK cytolytic activities for both lymphocyte populations were independent of HLA class I and CD1 molecules. The CD56 - T cells up-regulated CD56 with continued antigenic stimulation in the presence of interleukin 12, suggesting that CD8 + CD56 - T cells are NKT cells. However, CD56 + NKT cells expand poorly to continued stimulation. All mucin-stimulated NKT cells exhibited the activated/memory CD45RO phenotype. The NKT cell lines express the /ß T-cell receptor (TCR). The TCR repertoire was limited and varied with cell line, but was not the V 24Vß11 TCR typically associated with NKT cells. Whereas CD161 is generally considered a marker of NKT cells, the mucin-stimulated NKT cells did not express this marker. Thus, we have described two phenotypically distinct NKT types that do not display a biased TCR repertoire, but do display specificity for a tumor-specific peptide antigen (CTL-like activity), as well as HLA class I-deficient target cells (NK-like activity). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

Ex Vivo Expansion of CD8+CD56+ and CD8+CD56- Natural Killer T Cells Specific for MUC1 Mucin

Ex Vivo Expansion of CD8+CD56+ and CD8+CD56- Natural Killer T Cells Specific for MUC1 Mucin

Cancer Research , Volume 64 (3): 1171 – Feb 1, 2004

Abstract

Prostate cancers express MUC1, but nearly all metastatic cells lack HLA class I molecules. Thus, a lymphocyte population that can sense its antigenic environment, while also able to react to stimuli of natural killer (NK) cells, may be a more versatile effector cell population for antitumor immune responses. Herein, we report that tumor-specific MUC1 peptide, interleukin 2, and interleukin 12 act synergistically to stimulate the ex vivo expansion of CD8 + CD56 - T cells and CD8 + CD56 + natural killer T (NKT) cells from the peripheral blood mononuclear cells of prostate cancer patients, as well as healthy male and female donors. Both the CD56 + NKT cells and CD56 - T cells lysed allogeneic mucin-bearing target cells, as well as NK target cells, but not lymphokine-activated killer target cells. However, the CD56 + NKT cells displayed a 2-fold greater cytolytic activity than the CD56 - T cells. The mucin-specific cytolytic activity and NK cytolytic activities for both lymphocyte populations were independent of HLA class I and CD1 molecules. The CD56 - T cells up-regulated CD56 with continued antigenic stimulation in the presence of interleukin 12, suggesting that CD8 + CD56 - T cells are NKT cells. However, CD56 + NKT cells expand poorly to continued stimulation. All mucin-stimulated NKT cells exhibited the activated/memory CD45RO phenotype. The NKT cell lines express the /ß T-cell receptor (TCR). The TCR repertoire was limited and varied with cell line, but was not the V 24Vß11 TCR typically associated with NKT cells. Whereas CD161 is generally considered a marker of NKT cells, the mucin-stimulated NKT cells did not express this marker. Thus, we have described two phenotypically distinct NKT types that do not display a biased TCR repertoire, but do display specificity for a tumor-specific peptide antigen (CTL-like activity), as well as HLA class I-deficient target cells (NK-like activity).

Loading next page...
 
/lp/american-association-of-cancer-research/ex-vivo-expansion-of-cd8-cd56-and-cd8-cd56-natural-killer-t-cells-tT4ECvfA00

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 2004 by the American Association for Cancer Research.
ISSN
0008-5472
DOI
10.1158/0008-5472.CAN-3254-2
Publisher site
See Article on Publisher Site

Abstract

Prostate cancers express MUC1, but nearly all metastatic cells lack HLA class I molecules. Thus, a lymphocyte population that can sense its antigenic environment, while also able to react to stimuli of natural killer (NK) cells, may be a more versatile effector cell population for antitumor immune responses. Herein, we report that tumor-specific MUC1 peptide, interleukin 2, and interleukin 12 act synergistically to stimulate the ex vivo expansion of CD8 + CD56 - T cells and CD8 + CD56 + natural killer T (NKT) cells from the peripheral blood mononuclear cells of prostate cancer patients, as well as healthy male and female donors. Both the CD56 + NKT cells and CD56 - T cells lysed allogeneic mucin-bearing target cells, as well as NK target cells, but not lymphokine-activated killer target cells. However, the CD56 + NKT cells displayed a 2-fold greater cytolytic activity than the CD56 - T cells. The mucin-specific cytolytic activity and NK cytolytic activities for both lymphocyte populations were independent of HLA class I and CD1 molecules. The CD56 - T cells up-regulated CD56 with continued antigenic stimulation in the presence of interleukin 12, suggesting that CD8 + CD56 - T cells are NKT cells. However, CD56 + NKT cells expand poorly to continued stimulation. All mucin-stimulated NKT cells exhibited the activated/memory CD45RO phenotype. The NKT cell lines express the /ß T-cell receptor (TCR). The TCR repertoire was limited and varied with cell line, but was not the V 24Vß11 TCR typically associated with NKT cells. Whereas CD161 is generally considered a marker of NKT cells, the mucin-stimulated NKT cells did not express this marker. Thus, we have described two phenotypically distinct NKT types that do not display a biased TCR repertoire, but do display specificity for a tumor-specific peptide antigen (CTL-like activity), as well as HLA class I-deficient target cells (NK-like activity).

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Feb 1, 2004

There are no references for this article.